Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Zilucoplan Improved Efficacy Outcomes in Myasthenia Gravis

Key clinical point: Zilucoplan, a self-administered complement C5 inhibitor, improved measures of muscle weakness and daily function in patients with generalized myasthenia gravis.

Major finding: The mean change in Quantitative Myasthenia Gravis score was –6.0 points for zilucoplan 0.3 mg/kg and –3.2 for placebo (P = .05).

Study details: A randomized, placebo-controlled, phase 2 study including 44 adult patients with acetylcholine receptor autoantibody–positive generalized myasthenia gravis.

Disclosures: Ra Pharmaceuticals funded the study. The lead author reported disclosures related to Ra Pharmaceuticals, Alexion Pharmaceuticals, argenx, Viela Bio, and others.


Howard Jr JF et al. JAMA Neurol. 2020 Feb 17. doi: 10.1001/jamaneurol.2019.5125.